Free Trial
NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Price, News & Analysis

Eterna Therapeutics logo
$0.22 +0.01 (+5.42%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$0.21 -0.01 (-3.70%)
As of 04/25/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eterna Therapeutics Stock (NASDAQ:ERNA)

Key Stats

Today's Range
$0.19
$0.22
50-Day Range
$0.17
$0.35
52-Week Range
$0.15
$2.63
Volume
210,780 shs
Average Volume
2.79 million shs
Market Capitalization
$11.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Eterna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ERNA MarketRank™: 

Eterna Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Eterna Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eterna Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Eterna Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.90% of the float of Eterna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Eterna Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eterna Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eterna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Eterna Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.90% of the float of Eterna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Eterna Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eterna Therapeutics has recently decreased by 19.53%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Eterna Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for ERNA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.49% of the stock of Eterna Therapeutics is held by insiders.

  • Percentage Held by Institutions

    70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eterna Therapeutics' insider trading history.
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ERNA Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Elon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.
Ernexa Therapeutics Closes New Funding Round
Eterna changes name to Ernexa Therapeutics
Eterna hosts inaugural meeting of newly formed SAB
See More Headlines

ERNA Stock Analysis - Frequently Asked Questions

Eterna Therapeutics' stock was trading at $0.2940 at the start of the year. Since then, ERNA stock has decreased by 26.5% and is now trading at $0.2160.
View the best growth stocks for 2025 here
.

Eterna Therapeutics Inc. (NASDAQ:ERNA) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($4.92) EPS for the quarter. The company earned $0.49 million during the quarter.

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

Last Earnings
11/12/2024
Today
4/26/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERNA
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,670,000.00
Net Margins
-7,513.88%
Pretax Margin
-7,511.37%

Debt

Sales & Book Value

Annual Sales
$582,000.00
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
0.53

Miscellaneous

Free Float
5,168,000
Market Cap
$11.28 million
Optionable
No Data
Beta
4.79
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ERNA) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners